![Jean-Paul Kress](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jean-Paul Kress
Direktor/Vorstandsmitglied bei SANOFI
Profil
Jean-Paul Kress currently works at Syntimmune, Inc., as President & Director and Sanofi, as Independent Director from 2025.
Dr. Kress also formerly worked at Sanofi Pasteur MSD SNC, as President & Chief Executive Officer from 2011 to 2015, MorphoSys AG, as CEO & Chairman-Management Board from 2019 to 2024, ERYTech Pharma SA, as Chairman from 2019 to 2023, Sarepta Therapeutics, Inc., as Independent Director from 2015 to 2017, Quantum Genomics SA, as Director from 2018 to 2019, Biogen, Inc., as President-International & Executive Vice President from 2017 to 2018, Genzyme Corp., as Senior Vice President & Head-North America from 2015 to 2017, Gilead Sciences SAS, as Vice President-US Sales & Marketing, and Abbott France SAS, as General Manager-Denmark.
Dr. Kress received his undergraduate degree in 1991 and graduate degree in 1992 from École Normale Supérieure and doctorate degree in 1991 from Faculté De Médecine Necker Enfants Malades Université.
Aktuelle Nachrichten zu Jean-Paul Kress
Aktive Positionen von Jean-Paul Kress
| Unternehmen | Position | Beginn |
|---|---|---|
| SANOFI | Direktor/Vorstandsmitglied | 01.01.2025 |
Syntimmune, Inc.
 Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | Präsident | 03.01.2018 |
Ehemalige bekannte Positionen von Jean-Paul Kress
| Unternehmen | Position | Ende |
|---|---|---|
| MORPHOSYS AG | Vorstandsvorsitzender | 06.06.2024 |
ERYTech Pharma SA
 ERYTech Pharma SA Pharmaceuticals: MajorHealth Technology ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. The firm conducts research and development of innovative red blood cell-based therapeutics for cancer and orphan diseases. The company was founded by Pierre-Olivier Goineau and Yann Godfrin on November 22, 2004 and is headquartered in Lyon, France. | Vorsitzender | 23.06.2023 |
| QUANTUM GENOMICS | Direktor/Vorstandsmitglied | 24.06.2019 |
| BIOGEN INC. | Corporate Officer/Principal | 01.01.2018 |
| SAREPTA THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 06.06.2017 |
Ausbildung von Jean-Paul Kress
École Normale Supérieure | Graduate Degree |
Faculté De Médecine Necker Enfants Malades Université | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| SAREPTA THERAPEUTICS, INC. | Health Technology |
| BIOGEN INC. | Health Technology |
| QUANTUM GENOMICS | Health Technology |
| SANOFI | Health Technology |
| Private Unternehmen | 7 |
|---|---|
Syntimmune, Inc.
Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | Health Technology |
ERYTech Pharma SA
ERYTech Pharma SA Pharmaceuticals: MajorHealth Technology ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. The firm conducts research and development of innovative red blood cell-based therapeutics for cancer and orphan diseases. The company was founded by Pierre-Olivier Goineau and Yann Godfrin on November 22, 2004 and is headquartered in Lyon, France. | Health Technology |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
MorphoSys AG
 MorphoSys AG BiotechnologyHealth Technology MorphoSys AG is a biopharmaceutical company, which engages in the development and commercialization of cancer therapeutics. Its clinical programs focus on Pelabresib and Tulmimetostat. The company was founded by Andreas Pluckthun and Simon E. Moroney in July 1992 and is headquartered in Planegg, Germany. | Health Technology |
Sanofi Pasteur MSD SNC
 Sanofi Pasteur MSD SNC Pharmaceuticals: MajorHealth Technology Sanofi Pasteur MSD SNC is engaged in the wholesale of pharmaceutical products. The company was founded on August 16, 1993 and is headquartered in Lyon, France. | Health Technology |
Gilead Sciences SAS
 Gilead Sciences SAS Medical DistributorsDistribution Services Gilead Sciences SAS engages in wholesale distribution of pharmaceutical products. The company was founded in 1993 and is headquartered in Boulogne-Billancourt, France. | Distribution Services |
Abbott France SAS
 Abbott France SAS Medical DistributorsDistribution Services Part of Abbott Laboratories, Abbott France SAS wholesales pharmaceutical products. The company is based in Rungis, France. The CEO of the French company is Nathalie Guevel. | Distribution Services |
